藍光發展(600466.SH):控股股東累計被動減持5.02%股份
格隆匯9月23日丨藍光發展(600466.SH)公佈,公司於2021年9月23日收到控股股東藍光投資控股集團有限公司(“藍光集團”)出具的《四川藍光發展股份有限公司簡式權益變動報吿書》。藍光集團因股票質押融資違約事宜,以集中競價交易、大宗交易和司法拍賣方式被動減持公司股票。
其中,以集中競價和大宗交易被動減持公司股票4824.6021萬股;以司法拍賣方式被動減持公司股票1.04億股。截至2021年9月17日,信息披露義務人藍光集團累計減持公司股份1.52億股,佔公司總股本比例5.02%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.